KOLKATA
India
Chittaranjan National Cancer Institute
COVID 19, SARS-COV2 virus, JAK STAT Pathway, Baricitinib and Ruxolitinib
PI3K, HER+/HER2- Breast Cancer, Alpesilib, Buparlisib, Taselisib